Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315780611> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4315780611 endingPage "e271" @default.
- W4315780611 startingPage "e270" @default.
- W4315780611 abstract "Background: Dyslipidemia is a major factor in the development and progression of atherosclerotic diseases. Among dyslipidemias, familial hypercholesterolemia (FH) is a genetic disorder affecting approximately 34 million people worldwide, with 300,000 patients in Japan. Since homozygous FH in particular is resistant to existing therapies, there is an urgent need to develop new therapies to reduce the risk of cardiovascular disease (CVD) in patients with FH. Design and Method: We focused on angiopoietin-like protein 3 (ANGPTL3) as a novel therapeutic target for dyslipidemia. ANGPTL3 is known to inhibit lipoprotein lipase as well as angiogenesis. Mutations of this gene in humans were reported to have no apparent pathogenic effects and have been reported to reduce triglyceride (TG) and LDL cholesterol (LDL-C) levels in the blood and the risk of developing CVD. We have developed a peptide vaccine that induces anti-ANGPTL3 antibodies and produces a potent therapeutic effect on dyslipidemia. We vaccinated ob/ob mice, an obese mouse model of type 2 diabetes, with a total of three doses of vaccine every two weeks and analyzed the results. Results: The vaccine group (n = 12) showed significant reductions in blood TG concentration by 52%, LDL-C concentration by 41%, and small dense LDL-C concentration by 49% compared to the control group (n = 10). In addition, histologically fatty liver was improved, and analysis of TG accumulation in hepatocytes showed a 47% reduction in the vaccine group. Furthermore, vaccination reduced dyslipidemia and atherosclerosis in ApoE function-deficient mice, a model of severe familial hypercholesterolemia. Notability, the vaccine did not induce cytotoxic immunity against the mouse liver and ANGPTL3-producing organs. Conclusions: Based on these results, this vaccine is expected to be one of the effective treatments for atherosclerotic diseases." @default.
- W4315780611 created "2023-01-13" @default.
- W4315780611 creator A5025005882 @default.
- W4315780611 creator A5026881065 @default.
- W4315780611 creator A5030772606 @default.
- W4315780611 creator A5051836471 @default.
- W4315780611 creator A5059619179 @default.
- W4315780611 creator A5070669432 @default.
- W4315780611 creator A5086853921 @default.
- W4315780611 date "2023-01-01" @default.
- W4315780611 modified "2023-10-18" @default.
- W4315780611 title "PS-BPB03-5: DEVELOPMENT OF A THERAPEUTIC VACCINE FOR DYSLIPIDEMIA AND RELATED DISEASES TARGETING ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3)." @default.
- W4315780611 doi "https://doi.org/10.1097/01.hjh.0000915496.67037.8b" @default.
- W4315780611 hasPublicationYear "2023" @default.
- W4315780611 type Work @default.
- W4315780611 citedByCount "0" @default.
- W4315780611 crossrefType "journal-article" @default.
- W4315780611 hasAuthorship W4315780611A5025005882 @default.
- W4315780611 hasAuthorship W4315780611A5026881065 @default.
- W4315780611 hasAuthorship W4315780611A5030772606 @default.
- W4315780611 hasAuthorship W4315780611A5051836471 @default.
- W4315780611 hasAuthorship W4315780611A5059619179 @default.
- W4315780611 hasAuthorship W4315780611A5070669432 @default.
- W4315780611 hasAuthorship W4315780611A5086853921 @default.
- W4315780611 hasBestOaLocation W43157806111 @default.
- W4315780611 hasConcept C126322002 @default.
- W4315780611 hasConcept C134018914 @default.
- W4315780611 hasConcept C203014093 @default.
- W4315780611 hasConcept C2778096610 @default.
- W4315780611 hasConcept C2778163477 @default.
- W4315780611 hasConcept C2778913445 @default.
- W4315780611 hasConcept C2779120738 @default.
- W4315780611 hasConcept C2780072125 @default.
- W4315780611 hasConcept C2780948078 @default.
- W4315780611 hasConcept C43554185 @default.
- W4315780611 hasConcept C555293320 @default.
- W4315780611 hasConcept C71924100 @default.
- W4315780611 hasConceptScore W4315780611C126322002 @default.
- W4315780611 hasConceptScore W4315780611C134018914 @default.
- W4315780611 hasConceptScore W4315780611C203014093 @default.
- W4315780611 hasConceptScore W4315780611C2778096610 @default.
- W4315780611 hasConceptScore W4315780611C2778163477 @default.
- W4315780611 hasConceptScore W4315780611C2778913445 @default.
- W4315780611 hasConceptScore W4315780611C2779120738 @default.
- W4315780611 hasConceptScore W4315780611C2780072125 @default.
- W4315780611 hasConceptScore W4315780611C2780948078 @default.
- W4315780611 hasConceptScore W4315780611C43554185 @default.
- W4315780611 hasConceptScore W4315780611C555293320 @default.
- W4315780611 hasConceptScore W4315780611C71924100 @default.
- W4315780611 hasIssue "Suppl 1" @default.
- W4315780611 hasLocation W43157806111 @default.
- W4315780611 hasLocation W43157806112 @default.
- W4315780611 hasOpenAccess W4315780611 @default.
- W4315780611 hasPrimaryLocation W43157806111 @default.
- W4315780611 hasRelatedWork W1972011552 @default.
- W4315780611 hasRelatedWork W1976602105 @default.
- W4315780611 hasRelatedWork W2023154173 @default.
- W4315780611 hasRelatedWork W2033921535 @default.
- W4315780611 hasRelatedWork W2037584498 @default.
- W4315780611 hasRelatedWork W2058420421 @default.
- W4315780611 hasRelatedWork W2068768710 @default.
- W4315780611 hasRelatedWork W2072909849 @default.
- W4315780611 hasRelatedWork W2142407152 @default.
- W4315780611 hasRelatedWork W2809026100 @default.
- W4315780611 hasVolume "41" @default.
- W4315780611 isParatext "false" @default.
- W4315780611 isRetracted "false" @default.
- W4315780611 workType "article" @default.